Different Effect of Lanthanum Carbonate and Sevelamer Hydrochloride on Calcium Balance in Patients with Moderate to Advanced Chronic Kidney Disease

References

• Chue CD, Townend JN, Moody WE, et al. Cardiovascular effect of sevelamer in stage 3 in CKD. J Am Soc Nephrol. 2013;24:842–852. doi:10.1681/ASN.2012070719
   PubMed Web of Science ®Google Scholar
• Demer L, Tintut Y. The bone-vascular axis in chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19:349–353. doi:10.1097/MNH.0b013e32833a3d67
   PubMed Web of Science ®Google Scholar
• Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72:1255–1261. doi:10.1038/sj.ki.5002518
   PubMed Web of Science ®Google Scholar
• Yono S, McKee MD, Murry C, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;29:E10–E17.
   Google Scholar
• Hrushka KA, Mathew S. The role of the skeleton and phosphorus in the CKD mineral bone disease. Adv Chronic Kidney Dis. 2011;18:98–104. doi:10.1053/j.ackd.2011.01.001
   PubMed Web of Science ®Google Scholar
• Cunningham J, Locatelli F, Rodriquez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913–921. doi:10.2215/CJN.06040710
   PubMed Web of Science ®Google Scholar
• Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate, binders on mortality in hemodialysis patients. Kidney Int. 2007;72:1130–1137. doi:10.1038/sj.ki.5002466
   PubMed Web of Science ®Google Scholar
• Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23:1407–1415. doi:10.1681/ASN.2012030223
   PubMed Web of Science ®Google Scholar
• Wada K, Wada Y. Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial. Ther Apher Dial. 2014;18:353–360. doi:10.1111/1744-9987.12153
   PubMed Web of Science ®Google Scholar
• Toussaint ND, Lau KK, Polkinghorme KR, Kerr PG. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in hemodialysis: a pilot randomized controlled trial. Nephrology. 2011;16:290–298. doi:10.1111/j.1440-1797.2010.01412.x
   PubMed Web of Science ®Google Scholar
• Ruospo M, Ruospo M, Palmer SC, et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2018. doi:10.1002/14651858.CD006023.pub3
   PubMed Web of Science ®Google Scholar
• Zhai C-J, Yang X-W, Sun J, Wang R. Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol. 2015;47(3):527–535. doi:10.1007/s11255-014-0876-x
   PubMed Web of Science ®Google Scholar
• Liu Y-L, Lin -H-H, Yu -C-C, et al. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Ren Fail. 2006;28(8):701–707. doi:10.1080/08860220600925388
   PubMed Web of Science ®Google Scholar
• Wang C, Liu X, Zhou Y, et al. New conclusion regarding comparison of sevelamer and calcium-based phosphate binders in coronary-artery calcification for dialysis patients: a meta-analysis of randomized controlled trials. PLoS One. 2015;10:e0133938.
   PubMed Web of Science ®Google Scholar
• Prajapati VA, Galani VJ, Shah PR. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis. Saudi J Kidney Dis Transpl. 2014;25:530–538. doi:10.4103/1319-2442.132167
   PubMedGoogle Scholar
• Patel L, Bernard LM, Elder GJ. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. Clin J Am Soc Nephrol. 2016;11(2):232-44. doi:10.2215/CJN.06800615
   Google Scholar
• Taylor MJ, Elgazzar HA, Chaplin S, Goldsmith D, Molony DA. A economic evaluation of sevelamer in patients new to dialysis. Curr Med Res Opin. 2008;24:601–608. doi:10.1185/030079908X260853
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–252. doi:10.1046/j.1523-1755.2002.00434.x
   PubMed Web of Science ®Google Scholar
• Zhang C, Wen J, Li Z, Fan J. Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol. 2013;14:226. doi:10.1186/1471-2369-14-226
   PubMed Web of Science ®Google Scholar
• Behets GJ, Dams G, Damment SJ, Martin P, De Broe ME, D’Haese PC. Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders. Am J Physiol Renal Physiol. 2014;306:61–67. doi:10.1152/ajprenal.00219.2013
   Web of Science ®Google Scholar
• Phan O, Maillard M, Malluche HH, Stehle J-C, Funk F, Burnier M. Effect of sucroferric oxyhydroxide compared to lanthanum carbonate and sevelamer carbonate on phosphate homeostasis and vascular calcifications in rat model of chronic kidney disease. BioMed Res Int. 2015;2015:515606. doi:10.1155/2015/515606
   PubMed Web of Science ®Google Scholar
• Robijn S, Vervaet BA, Hoppe B, D’Haese PC, Verhulst A. Lanthanum carbonate inhibits intestinal oxalate absorption and prevents nephrocalcinosis after oxalate loading in rats. J Urol. 2013;189:1960–1966. doi:10.1016/j.juro.2012.12.004
   PubMed Web of Science ®Google Scholar
• Gonzalez-Paara E, Egonzalez-Causa ML, Galan A, et al. Lanthanum carbonate reduces FGF-23 in chronic kidney disease stage 3 patients. Nephrol Dial Transplant. 2011;26:2567–2571. doi:10.1093/ndt/gfr144
   PubMed Web of Science ®Google Scholar
• Spasovski GB, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant. 2006;21:2217–2224. doi:10.1093/ndt/gfl146
   PubMed Web of Science ®Google Scholar
• Iwata Y, Wada T, Yokoyama H, et al. Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels. Ren Fail. 2006;28:701–707.
   PubMedGoogle Scholar
• Spatz C, Roe K, Lehman E, Verma N. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease. Nephron Clin Pract. 2013;123:61–66. doi:10.1159/000351811
   PubMedGoogle Scholar
• Muras K, Masajtis-Zagajewska A, Nowicki M. Diabetes modifies effect of high-phosphate diet on fibroblast growth factor-23 in chronic kidney disease. J Clin Endocrinol Metab. 2013;98:E1901–E1908. doi:10.1210/jc.2013-2418
   PubMed Web of Science ®Google Scholar
• Oliveira RB, Cancela ALE, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010;5:286–291. doi:10.2215/CJN.05420709
   PubMed Web of Science ®Google Scholar
• Pierce D, Hossack S, Poole L, et al. The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. Nephrol Dial Transplant. 2011;26:1615–1621. doi:10.1093/ndt/gfq598
   PubMed Web of Science ®Google Scholar